Suppression of tumour growth from transplanted astrocytoma cells transfected with luciferase in mice by bioluminescence mediated, systemic, photodynamic therapy

Background: Grade 4 astrocytomas are usually incurable due to their diffusely infiltrative nature. Photodynamic therapy (PDT) is a promising therapeutic option, but external light delivery is impractical when cancer cells infiltrate unknown areas of normal brain. Hence the search for endogenous sour...

Full description

Saved in:
Bibliographic Details
Main Authors: Jane Ng, Nico Henriquez, Neil Kitchen, Norman Williams, Marco Novelli, Dahmane Oukrif, Alexander MacRobert, Stephen Bown
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Photodiagnosis and Photodynamic Therapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1572100023006506
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846128267488133120
author Jane Ng
Nico Henriquez
Neil Kitchen
Norman Williams
Marco Novelli
Dahmane Oukrif
Alexander MacRobert
Stephen Bown
author_facet Jane Ng
Nico Henriquez
Neil Kitchen
Norman Williams
Marco Novelli
Dahmane Oukrif
Alexander MacRobert
Stephen Bown
author_sort Jane Ng
collection DOAJ
description Background: Grade 4 astrocytomas are usually incurable due to their diffusely infiltrative nature. Photodynamic therapy (PDT) is a promising therapeutic option, but external light delivery is impractical when cancer cells infiltrate unknown areas of normal brain. Hence the search for endogenous sources to generate light at cancer cells. In vitro, astrocytoma cells, transfected with firefly luciferase, can be killed by bioluminescence-mediated PDT (bPDT). This study asks if bPDT can suppress tumour growth In vivo, when all components of treatment are administered systemically. Methods: Transfected astrocytoma cells were injected subcutaneously or intra-cranially in athymic CD1 nu/nu mice. bPDT required ip bolus of mTHPC (photosensitiser) and delivery of the d-luciferin substrate over 7 days via an implanted osmotic pump. Control animals had no treatment, photosensitiser only or d-luciferin only. For subcutaneous tumours, size and BLI (light emitted after d-luciferin bolus) were measured before and every 2 days after PDT. For intracranial tumours, monitoring was weekly BLI. Results: For subcutaneous tumours, there was significant suppression of the tumour growth rate (P<0.05), and absolute tumour size (P<0.01) after bPDT. Proliferation of subcutaneous and intracranial tumours (monitored by BrdU uptake) was significantly reduced in treated mice. (P<0.001) Conclusions: This study reports bPDT suppression of tumour growth from luciferase transfected astrocytoma cells with all components of treatment given systemically, as required for effective management of recurrent astrocytomas in unknown sites. However, research on systemic bPDT is needed to establish whether effects on non-transfected tumours can be achieved without any unacceptable effects on normal tissues.
format Article
id doaj-art-a5674daf4e4b47ac9be8e00ae67d887f
institution Kabale University
issn 1572-1000
language English
publishDate 2024-02-01
publisher Elsevier
record_format Article
series Photodiagnosis and Photodynamic Therapy
spelling doaj-art-a5674daf4e4b47ac9be8e00ae67d887f2024-12-11T05:55:19ZengElsevierPhotodiagnosis and Photodynamic Therapy1572-10002024-02-0145103923Suppression of tumour growth from transplanted astrocytoma cells transfected with luciferase in mice by bioluminescence mediated, systemic, photodynamic therapyJane Ng0Nico Henriquez1Neil Kitchen2Norman Williams3Marco Novelli4Dahmane Oukrif5Alexander MacRobert6Stephen Bown7UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom; National Medical Laser Centre (now Department of Targeted Intervention, Division of Surgery and Interventional Science), University College London, Charles Bell House 43-45 Foley Street, London W1W 7TS, United KingdomUCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, United KingdomVictor Horsley Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, UCLH NHS Trust, Queen Square, London WC1 3BG, United Kingdom of Great Britain and Northern Ireland, United KingdomDivision of Surgery &amp; Interventional Science, University College London, Charles Bell House, 43-45 Foley Street London W1W 7TS, United KingdomDepartment of Cellular Pathology, University College Hospital, London, 60 Whitfield Street, London W1T 4EU, United KingdomDepartment of Cellular Pathology, University College Hospital, London, 60 Whitfield Street, London W1T 4EU, United KingdomNational Medical Laser Centre (now Department of Targeted Intervention, Division of Surgery and Interventional Science), University College London, Charles Bell House 43-45 Foley Street, London W1W 7TS, United KingdomNational Medical Laser Centre (now Department of Targeted Intervention, Division of Surgery and Interventional Science), University College London, Charles Bell House 43-45 Foley Street, London W1W 7TS, United Kingdom; Corresponding author.Background: Grade 4 astrocytomas are usually incurable due to their diffusely infiltrative nature. Photodynamic therapy (PDT) is a promising therapeutic option, but external light delivery is impractical when cancer cells infiltrate unknown areas of normal brain. Hence the search for endogenous sources to generate light at cancer cells. In vitro, astrocytoma cells, transfected with firefly luciferase, can be killed by bioluminescence-mediated PDT (bPDT). This study asks if bPDT can suppress tumour growth In vivo, when all components of treatment are administered systemically. Methods: Transfected astrocytoma cells were injected subcutaneously or intra-cranially in athymic CD1 nu/nu mice. bPDT required ip bolus of mTHPC (photosensitiser) and delivery of the d-luciferin substrate over 7 days via an implanted osmotic pump. Control animals had no treatment, photosensitiser only or d-luciferin only. For subcutaneous tumours, size and BLI (light emitted after d-luciferin bolus) were measured before and every 2 days after PDT. For intracranial tumours, monitoring was weekly BLI. Results: For subcutaneous tumours, there was significant suppression of the tumour growth rate (P<0.05), and absolute tumour size (P<0.01) after bPDT. Proliferation of subcutaneous and intracranial tumours (monitored by BrdU uptake) was significantly reduced in treated mice. (P<0.001) Conclusions: This study reports bPDT suppression of tumour growth from luciferase transfected astrocytoma cells with all components of treatment given systemically, as required for effective management of recurrent astrocytomas in unknown sites. However, research on systemic bPDT is needed to establish whether effects on non-transfected tumours can be achieved without any unacceptable effects on normal tissues.http://www.sciencedirect.com/science/article/pii/S1572100023006506Grade 4 astrocytoma cellsTransfection of cells with luciferasemTHPCBioluminescence mediated photodynamic therapy (bPDT)Subcutaneous and intracranial tumour growth suppression
spellingShingle Jane Ng
Nico Henriquez
Neil Kitchen
Norman Williams
Marco Novelli
Dahmane Oukrif
Alexander MacRobert
Stephen Bown
Suppression of tumour growth from transplanted astrocytoma cells transfected with luciferase in mice by bioluminescence mediated, systemic, photodynamic therapy
Photodiagnosis and Photodynamic Therapy
Grade 4 astrocytoma cells
Transfection of cells with luciferase
mTHPC
Bioluminescence mediated photodynamic therapy (bPDT)
Subcutaneous and intracranial tumour growth suppression
title Suppression of tumour growth from transplanted astrocytoma cells transfected with luciferase in mice by bioluminescence mediated, systemic, photodynamic therapy
title_full Suppression of tumour growth from transplanted astrocytoma cells transfected with luciferase in mice by bioluminescence mediated, systemic, photodynamic therapy
title_fullStr Suppression of tumour growth from transplanted astrocytoma cells transfected with luciferase in mice by bioluminescence mediated, systemic, photodynamic therapy
title_full_unstemmed Suppression of tumour growth from transplanted astrocytoma cells transfected with luciferase in mice by bioluminescence mediated, systemic, photodynamic therapy
title_short Suppression of tumour growth from transplanted astrocytoma cells transfected with luciferase in mice by bioluminescence mediated, systemic, photodynamic therapy
title_sort suppression of tumour growth from transplanted astrocytoma cells transfected with luciferase in mice by bioluminescence mediated systemic photodynamic therapy
topic Grade 4 astrocytoma cells
Transfection of cells with luciferase
mTHPC
Bioluminescence mediated photodynamic therapy (bPDT)
Subcutaneous and intracranial tumour growth suppression
url http://www.sciencedirect.com/science/article/pii/S1572100023006506
work_keys_str_mv AT janeng suppressionoftumourgrowthfromtransplantedastrocytomacellstransfectedwithluciferaseinmicebybioluminescencemediatedsystemicphotodynamictherapy
AT nicohenriquez suppressionoftumourgrowthfromtransplantedastrocytomacellstransfectedwithluciferaseinmicebybioluminescencemediatedsystemicphotodynamictherapy
AT neilkitchen suppressionoftumourgrowthfromtransplantedastrocytomacellstransfectedwithluciferaseinmicebybioluminescencemediatedsystemicphotodynamictherapy
AT normanwilliams suppressionoftumourgrowthfromtransplantedastrocytomacellstransfectedwithluciferaseinmicebybioluminescencemediatedsystemicphotodynamictherapy
AT marconovelli suppressionoftumourgrowthfromtransplantedastrocytomacellstransfectedwithluciferaseinmicebybioluminescencemediatedsystemicphotodynamictherapy
AT dahmaneoukrif suppressionoftumourgrowthfromtransplantedastrocytomacellstransfectedwithluciferaseinmicebybioluminescencemediatedsystemicphotodynamictherapy
AT alexandermacrobert suppressionoftumourgrowthfromtransplantedastrocytomacellstransfectedwithluciferaseinmicebybioluminescencemediatedsystemicphotodynamictherapy
AT stephenbown suppressionoftumourgrowthfromtransplantedastrocytomacellstransfectedwithluciferaseinmicebybioluminescencemediatedsystemicphotodynamictherapy